Please Wait a Moment
X

CTS History

01Dec

Babesia

SuperUser Account |01 Dec, 2015 | Return|

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

Pooled Babesia

Pooled Babesia

Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...

Read More >
Zika Testing

Zika Testing

In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...

Read More >
Disaster Reliability via Merged Information Systems

Disaster Reliability via Merged Information Systems

In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...

Read More >
Implementation of a COVID-19 Test

Implementation of a COVID-19 Test

CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...

Read More >

Research Consortium

CTS Research Consortium was established to further CTS’s leadership in infectious disease research....

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...

Read More >